Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2013 by Nationwide Children's Hospital.
Recruitment status was:  Active, not recruiting
Genentech, Inc.
Information provided by (Responsible Party):
Robert G. Castile, Nationwide Children's Hospital Identifier:
First received: September 10, 2005
Last updated: August 19, 2013
Last verified: August 2013

This is a study to find out whether Pulmozyme is effective for clearing mucus from the airways of children with cystic fibrosis less than 3 ½ years of age. Pulmozyme is given using a nebulizer and is now widely used in older children and adults with cystic fibrosis. In adults and older children, studies have shown that daily use of Pulmozyme improves lung function and decreases the number of lung infections requiring hospital treatment. Pulmozyme has been approved by the Food and Drug Administration for use in children over 5 years old and adults with cystic fibrosis. Pulmozyme has also been approved by the FDA for use in children with cystic fibrosis less than 5 years old based upon studies showing that it is safe in this age group and that it does get into the airway tubes as well in infants and toddlers as it does in older children and adults. Currently Pulmozyme is not widely used in children with cystic fibrosis younger than 5 years because no study has clearly shown that inhaling Pulmozyme daily improves lung function or improves clearance of mucus from the airway tubes in very young children. This study will measure whether Pulmozyme improves lung function and mucous clearance from the lungs in children with cystic fibrosis less than 3 ½ years of age.

This study will compare Pulmozyme to a placebo. During the study infants and young children with cystic fibrosis will be treated with Pulmozyme for 6 months and placebo for 6 months. The study medicines will be inhaled at home once a day from a nebulizer for a period of one year. Half of the children will be treated with Pulmozyme for the first 6 months of the study and half will receive the placebo. At the 6 month point the group receiving Pulmozyme will be changed to the placebo and the group receiving placebo will be changed to Pulmozyme. The order of the 6 month treatment periods is randomized. This study is blinded. The study doctor and his staff will not know who is receiving Pulmozyme or placebo at any time during the study.

Whether Pulmozyme works will be measured using infant lung function tests and by doing a special 3-D x-ray of the child's chest (a high resolution CT or HRCT) at the beginning of the study, at 6 months and at 12 month after starting study. The study will not change the regular clinical care.

Condition Intervention Phase
Cystic Fibrosis
Drug: Recombinant Human DNase (Pulmozyme)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Pulmozyme in Infants and Young Children With Cystic Fibrosis

Resource links provided by NLM:

Further study details as provided by Nationwide Children's Hospital:

Primary Outcome Measures:
  • Chest CT (HRCT Score) [ Time Frame: 6 months ]
  • Infant Pulmonary Function Tests (FEV0.5, FEF25-75) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Antibiotic treatment days [ Time Frame: per 6 month interval ]

Enrollment: 24
Study Start Date: January 2005
Estimated Study Completion Date: July 2015
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
once daily nebulized rhDNAse
Drug: Recombinant Human DNase (Pulmozyme)
Comparison of 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
Other Name: Pulmozyme
Placebo Comparator: 2
once daily nebulized vehicle
Drug: Recombinant Human DNase (Pulmozyme)
Comparison of 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
Other Name: Pulmozyme


Ages Eligible for Study:   1 Month to 30 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age < 30 months
  • Diagnosis of CF based on clinical features consistent with CF as well as 1 of the 2 following criteria: a) two sweat chlorides >60 mEq/L (by quantitative pilocarpine iontophoresis), b) genotype with 2 identifiable mutations consistent with CF.
  • Informed consent by parent or legal guardian

Exclusion Criteria:

  • Previous treatment with Pulmozyme
  • Hospitalization or treatment with IV antibiotics with 14 days of initial study visit
  • Acute intercurrent respiratory infection, defined as any of the following symptoms within the preceding 48 hours: 1) fever > 38 degrees C, 2) new onset of coryza or other upper respiratory symptoms, 3) increase in cough, wheezing, or respiratory rate
  • History of adverse reaction to sedation
  • Oxyhemoglobin saturation <90% on room air
  • Severe upper airway obstruction as determined by site PI (severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnea)
  • Hemodynamically significant congenital heart disease or diagnosed arrhythmias
  • History of hemoptysis
  • History of previous pulmonary air leak (pneumothorax)
  • Diagnosed seizure disorder necessitating current anticonvulsive therapy. A history of febrile seizures is not an exclusion criterion.
  • Use of Investigational drug(s) within 60 days or 5 half-lives of enrollment in this study.
  • Known allergy to Chinese Hamster Ovary-derived biological products or any component of the placebo or active drug formulations.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00179998

United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Sponsors and Collaborators
Nationwide Children's Hospital
Genentech, Inc.
Principal Investigator: Robert G Castile, MD The Research Institute at Nationwide Children's Hospital
  More Information

Responsible Party: Robert G. Castile, Professor of Pediatrics, Nationwide Children's Hospital Identifier: NCT00179998     History of Changes
Other Study ID Numbers: Z2910s
Study First Received: September 10, 2005
Last Updated: August 19, 2013

Keywords provided by Nationwide Children's Hospital:
Cystic fibrosis
Pulmonary function
Computed tomography

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases processed this record on May 24, 2017